Clinical trials: Risk Management
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
High Bleeding Risk, Coronary Artery Disease
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with…
- Conditions
- High Bleeding Risk, Coronary Artery Disease, PCI
- Trial name
- MASTER DAPT (NCT03023020)
- Testing
- Aspirin, P2Y12 inhibitor
- Where
- 138 sites in Argentina, Australia and 28 more
- Volunteers
- 4,579 people
- Sponsor
- ECRI bv
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC
Longitudinal Studies, Prospective Studies
Clinical Time and Temporal Dynamics Study (CLIN-TIME)
TH-CLINICAL-TIME is a prospective, longitudinal observational study evaluating how changes in clinical measurements over time may help researchers better understand patient health trajectories and clinically meaningful outcomes.
- Conditions
- Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests
- Trial name
- CLIN-TIME (NCT07812831)
- Testing
- No Study-Assigned Intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Cardiac Decompensation
Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices
This is planned as a feasibility study. The objective is to evaluate a specially designed patient adherence and monitoring software on standard mobile devices in remote monitoring of heart failure patients.
- Trial name
- REMOTE-HF-1 (NCT01430936)
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 51 people
- Sponsor
- Aventyn, Inc.
Melanoma
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Patients with malignant melanoma who had undergone surgery will receive adjuvant treatment with high-dose Intron A for one year.
- Trial name
- NCT00723710
- Testing
- Intron A (interferon alfa-2b; SCH 30500)
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression
Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression
The purpose of this study is to determine if medical, biological, psychological, and social risk factors can be used to develop algorithms that will predict perinatal depression (PND).
- Trial name
- NCT03144752
- Where
- United States
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Contrast Medium
Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid
Iopromide (trade name is Ultravist) is on the market for more than 30 years and has been used more than 250 million times as X-ray contrast medium for patients.
- Trial name
- UVIA (NCT03622801)
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- Germany
- Volunteers
- 133,331 people
- Sponsor
- Bayer
Hypertension, Hypercholesterolemia
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
- Trial name
- CRUCIAL (NCT00407537)
- Testing
- Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 125 sites in Costa Rica, Croatia and 18 more
- Volunteers
- 1,531 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cardiovascular Risk Factors, Cardiovascular Diseases
Management of Cardiovascular Risk Factors
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases.
- Trial name
- NCT00848380
- Where
- 36 sites in Switzerland
- Volunteers
- 1,492 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Contrast Media
Primovist / Eovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Primovist/Eovist, will be asked to participate.
- Trial name
- PERI (NCT00908596)
- Testing
- Gadoxetic acid disodium (Primovist, BAY86-4873)
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 357 people
- Sponsor
- Bayer
Engagement, Patient, Quality of Life
SimpleC Wellness Platform With Social Robot Interaction (Long-term)
This study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Quality of Life, Mood, Aging Well
- Trial name
- NCT05599503
- Testing
- Behavioral Interventions, Robot Interventions
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- SimpleC, LLC
Severe Hypertriglyceridemia (sHTG)
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
- Trial name
- NCT03452228
- Testing
- evinacumab
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Hereditary Cancer Syndromes, Clinical Decision Support
Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer
The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer. The trial will also help improve the software platform (Nest).
- Trial name
- NCT06654466
- Testing
- Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nest Genomics
Indeterminate Pulmonary Nodule
Nodify Lung Testing for Pulmonary Nodules
The STRATIFY Study is an observational study for adults age 40 or older who have a lung nodule that is not clearly benign or cancerous. The study will enroll up to 1,000 participants at about 10-12 U.S.
- Trial name
- STRATIFY (NCT07858552)
- Volunteers
- 1,000 people
- Sponsor
- Biodesix, Inc.
Hyperkalemia
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil
This is a descriptive, retrospective study involving patients from private cardiology, nephrology, and dialysis clinics in Brazil who participated in the National Hyperkalaemia Diagnosis Campaign.
- Trial name
- HOPE (NCT07370194)
- Where
- Brazil
- Volunteers
- 6,215 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Coronary Arteriosclerosis
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.
- Trial name
- NCT00319449
- Testing
- Ezetimibe, Atorvastatin 10 mg
- Volunteers
- 22 people
- Sponsor
- Organon and Co
Dyslipidemia
A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.
This study is a local PCO sponsored, interventional, non-drug study to evaluate the efficacy of a health tele-counselling program in reducing cardiovascular risk in dyslipidemic patients.
- Trial name
- DISSEMINATE (NCT00708370)
- Testing
- COACH
- Where
- 22 sites in Malaysia
- Volunteers
- 297 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Moderate to High-risk Noncardiac Surgery
Hypotension Prediction Index (HPI) SMART-BP Trial
A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.
- Trial name
- NCT05105477
- Testing
- AcumenTM HPI Software Feature, Non-protocolized Standard of Care
- Where
- 11 sites in United States
- Volunteers
- 407 people
- Sponsor
- Edwards Lifesciences
Diabetes Mellitus, Type 1, Autoimmune Diseases
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2…
- Conditions
- Diabetes Mellitus, Type 1, Autoimmune Diseases, Prevention
- Trial name
- NCT05683990
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Diamyd Medical AB